Adulteration of Brain Health (Cognitive, Mood, and Sleep Enhancement) Food Supplements by the Addition of Pharmaceutical Drugs: A Comprehensive Review of Analytical Approaches and Trends.

Foods

Centro de Investigação de Montanha (CIMO), Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253 Bragança, Portugal.

Published: March 2024

In recent years, the consumption of dietary supplements has grown worldwide, particularly in developed regions. However, this growing market has also become a prime target for adulteration practices, with some manufacturers illegally adding pharmaceuticals into plant-based food supplements (PFS) to enhance their effects. While extensive research has focused on detecting adulterant drugs in PFS tailored for improving sexual performance, weight loss, and muscle building, less attention has been given to supplements intended for mood enhancement, sleep aid, and cognitive function (nootropics). Nonetheless, recent reports indicate an increasing level of adulteration within this group of PFS. Therefore, this review aims at providing a comprehensive overview on the adulteration of PFS tailored for brain health, with a focus on the analytical techniques utilized for detection while also presenting data on consumption patterns and the prevalence of reported adulterants. Considering that the detection of such fraudulent practices primarily relies on chromatographic techniques coupled with mass spectrometry (MS), the developments in this field comprising either targeted or untargeted analysis of pharmaceutical adulterants are discussed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10969376PMC
http://dx.doi.org/10.3390/foods13060908DOI Listing

Publication Analysis

Top Keywords

brain health
8
food supplements
8
pfs tailored
8
adulteration
4
adulteration brain
4
health cognitive
4
cognitive mood
4
mood sleep
4
sleep enhancement
4
enhancement food
4

Similar Publications

Article Synopsis
  • A study evaluated the impacts of divalproex sodium on brain volumes in patients with mild to moderate Alzheimer’s disease using MRI scans over 24 months.
  • The results indicated that participants receiving divalproex experienced a significantly higher decline in hippocampal and brain volumes compared to those on placebo, along with a faster decline in cognitive function as measured by the Mini-Mental State Examination.
  • The findings suggest that divalproex treatment is linked to accelerated brain volume loss and potentially increased cognitive impairment, although the long-term effects remain unclear.
View Article and Find Full Text PDF
Article Synopsis
  • The study tested whether divalproex sodium (valproate) could prevent or delay agitation and psychosis in individuals with moderate Alzheimer's disease, enrolling 313 participants.
  • After two years of treatment, results showed no significant difference between the valproate and placebo groups regarding the time to development of agitation or psychosis.
  • Additionally, the valproate group experienced more side effects and showed greater reductions in brain volume, indicating potential adverse effects of the treatment.
View Article and Find Full Text PDF

Objective: To delineate the trajectories of Aβ42 level in cerebrospinal fluid (CSF), fludeoxyglucose F18 (FDG) uptake using positron emission tomography, and hippocampal volume using magnetic resonance imaging and their relative associations with cognitive change at different stages in aging and Alzheimer disease (AD).

Design: Cohort study.

Setting: The 59 study sites for the Alzheimer's Disease Neuroimaging Initiative.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!